Generation Bio Co. (GBIO)

NASDAQ: GBIO · IEX Real-Time Price · USD
2.960
-0.130 (-4.21%)
At close: Mar 18, 2024, 4:00 PM
2.890
-0.070 (-2.36%)
After-hours: Mar 18, 2024, 5:39 PM EDT

Company Description

Generation Bio Co. develops non-viral genetic medicines for the treatment of rare and prevalent diseases.

The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems.

It uses its platform for developing a portfolio of programs for treating cancer, autoimmune, hematologic disorders, prioritizing sickle cell, beta-thalassemia, and hemophilia A diseases, as well as for other tissues and cell types, including retina, skeletal muscle, and central nervous system.

The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017.

Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Generation Bio Co.
Generation Bio Co. logo
Country United States
Founded 2016
IPO Date Jun 12, 2020
Industry Biotechnology
Sector Healthcare
Employees 174
CEO Dr. Cameron Geoffrey McDonough M.D.

Contact Details

Address:
301 Binney Street
Cambridge, Massachusetts 02142
United States
Phone 857-529-5908
Website generationbio.com

Stock Details

Ticker Symbol GBIO
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $19.00
CIK Code 0001733294
CUSIP Number 37148K100
ISIN Number US37148K1007
Employer ID 81-4301281
SIC Code 2834

Key Executives

Name Position
Dr. Cameron Geoffrey McDonough M.D. President, Chief Executive Officer and Director
Dr. Matthew Norkunas M.B.A., M.D. Chief Financial Officer
Dr. Matthew Stanton Ph.D. Chief Scientific Officer
Dr. Mark D. Angelino Ph.D. Co-Founder
Dr. Robert Kotin Ph.D. Co-Founder
Antoinette Paone M.B.A., M.S. Chief Operating Officer
Yalonda Howze J.D. Chief Legal Officer and Secretary
Jasmin Tower Chief Human Resources Officer
Dr. Phillip Samayoa Ph.D. Chief Strategy Officer

Latest SEC Filings

Date Type Title
Mar 6, 2024 S-8 Securities to be offered to employees in employee benefit plans
Mar 6, 2024 10-K Annual Report
Mar 6, 2024 8-K Current Report
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 13, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 9, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 9, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 2, 2024 8-K Current Report
Jan 8, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Jan 8, 2024 8-K Current Report